Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Providence, Rhode Island


Purpose:

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.


Criteria:

Inclusion Criteria: - Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant - No more than 3 prior chemotherapy regimens in the metastatic setting - Must have at least one target lesion that is radiographically measurable - Good performance status - No history of or current brain or leptomeningeal disease


NCT ID:

NCT00080262


Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb


Backup Contact:

N/A


Location Contact:

Providence, Rhode Island
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.